中化生 (1762)

About 中化生

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DMF or COS, and other API products. It also provides specialty API immunosuppressants, including mycophenolate mofetil, rapamycin, and tacrolimus; derivative of rapamycin, such as everolimus, temsirolimus, zotarolimus, and biolimus; and echinocandin comprising caspofungin, micafungin, and anidulafungin. In addition, the company is also involved in contract manufacturing and research services. It exports its products. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. and changed its name to Chunghwa Chemical Synthesis & Biotech Co., Ltd. in January 2003. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.

Headquarters: New Taipei City, TW · Website: https://www.ccsb.com.tw

Frequently asked questions about 中化生 (1762)

What is 中化生 (1762)?

中化生 (1762) is a publicly traded company in the Healthcare sector (化學生技醫療), listed on TWSE. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.